Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study

BACKGROUND AND AIMS: This analysis examined the long-term safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis [UC] with ≥ 4 years of follow-up in the phase 2 TOUCHSTONE open-label extension [OLE]. METHODS: Patients receiving placebo or ozanimod HCl 0.5 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J, Feagan, Brian G, Hanauer, Stephen, Vermeire, Severine, Ghosh, Subrata, Liu, Wenzhong J, Petersen, AnnKatrin, Charles, Lorna, Huang, Vivian, Usiskin, Keith, Wolf, Douglas C, D’Haens, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256627/
https://www.ncbi.nlm.nih.gov/pubmed/33438008
http://dx.doi.org/10.1093/ecco-jcc/jjab012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256627/
https://www.ncbi.nlm.nih.gov/pubmed/33438008
http://dx.doi.org/10.1093/ecco-jcc/jjab012

Ejemplares similares